Avalo Therapeutics (NASDAQ:AVTX) Stock Price Down 5.4% – What’s Next?

Posted by Brian Himes on Jul 22nd, 2026

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) fell 5.4% during trading on Monday . The company traded as low as $18.37 and last traded at $18.33. Approximately 109,378 shares were traded during mid-day trading, a decline of 91% from the average session volume of 1,231,273 shares. The stock had previously closed at $19.37.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings lowered shares of Avalo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Leerink Partners assumed coverage on shares of Avalo Therapeutics in a report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target for the company. Piper Sandler restated an “overweight” rating and set a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Wedbush decreased their price target on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Finally, Mizuho upped their price target on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Thirteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.80.

Check Out Our Latest Analysis on Avalo Therapeutics

Avalo Therapeutics Stock Performance

The company has a market cap of $995.58 million, a PE ratio of -3.45 and a beta of 0.78. The business’s 50-day moving average is $16.79 and its 200 day moving average is $16.09.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. Equities research analysts anticipate that Avalo Therapeutics, Inc. will post -2.58 EPS for the current fiscal year.

Insider Activity

In other Avalo Therapeutics news, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total value of $1,514,020.71. Following the transaction, the insider owned 3,634 shares in the company, valued at approximately $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 1,450 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the transaction, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $931,968. This trade represents a 2.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 93,428 shares of company stock valued at $1,762,722. 4.46% of the stock is currently owned by company insiders.

Institutional Trading of Avalo Therapeutics

Large investors have recently modified their holdings of the business. UBS Group AG raised its position in Avalo Therapeutics by 956.9% during the 4th quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after purchasing an additional 432,608 shares during the last quarter. Moody Aldrich Partners LLC bought a new stake in shares of Avalo Therapeutics in the 4th quarter worth approximately $2,419,000. Nan Fung Trinity HK Ltd. purchased a new position in shares of Avalo Therapeutics during the fourth quarter valued at approximately $3,432,000. Jennison Associates LLC purchased a new position in shares of Avalo Therapeutics during the fourth quarter valued at approximately $8,637,000. Finally, 683 Capital Management LLC bought a new position in shares of Avalo Therapeutics during the fourth quarter valued at approximately $1,032,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

(Get Free Report)

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.